Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65.88 USD | +1.66% | +2.72% | +15.87% |
04-29 | North American Morning Briefing : Investors Brace -2- | DJ |
04-26 | Stifel Upgrades LeMaitre Vascular to Buy From Hold, Adjusts Price Target to $75 From $59 | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 39.2 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.87% | 1.45B | C- | ||
+7.42% | 217B | B | ||
+6.09% | 183B | B- | ||
+9.73% | 131B | B- | ||
+24.08% | 106B | A- | ||
-0.95% | 62.16B | A- | ||
+9.93% | 51.02B | B+ | ||
+4.81% | 50.89B | B+ | ||
-1.56% | 40.16B | A | ||
+0.36% | 34.79B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LMAT Stock
- Ratings LeMaitre Vascular, Inc.